Why is it important?
Today, one in five French people is over 60 years old, and in 2050 one in three will be. Aging-associated diseases are assuming ever-greater proportions. The second leading neurodegenerative disease, Parkinson’s disease currently affects around 150,000 people in France. While symptom relief treatments exist, they are accompanied by very unpleasant side effects and their effectiveness diminishes as the disease progresses.